Skip to content
Biodatica
Start free

Investigator

Christopher Barron

EMBIOSYS INC. · funded by NCI

Companies
1

Resolved onto their grants.

Grants
2

Federal awards on file.

Non-dilutive funding
$1.6M

Summed across those awards.

First award
Jun 1, 2024

Latest Sep 17, 2025.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R44

    CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast Cancer

    $1.4M

    Sep 17, 2025NCIEMBIOSYS INC.NIH RePORTER · 11313323 (opens the source filing in a new tab)

  2. R43

    DEVELOPMENT OF A WEARABLE, NON-INVASIVE, TREATMENT DEVICE FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC)

    $189k

    Jun 1, 2024NCIEMBIOSYS INC.NIH RePORTER · 11086646 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources